SERPINA1 and non-small cell lung carcinoma: The use of 2D-DIGE for studying serum proteome profiles at the baseline and progression of the disease showed that alpha-1-antitrypsin (AAT) was highly upregulated in progressive diseases (PD) compared to baseline levels in advanced NSCLC patients treated with erlotinib or gefitinib [65].